Insider Selling: Maplight Therapeutics (NASDAQ:MPLT) Insider Sells 24,052 Shares of Stock

Maplight Therapeutics, Inc. (NASDAQ:MPLT) insider Erin Pennock Foff sold 24,052 shares of Maplight Therapeutics stock in a transaction on Wednesday, May 6th. The stock was sold at an average price of $28.76, for a total transaction of $691,735.52. Following the transaction, the insider directly owned 350,497 shares of the company’s stock, valued at $10,080,293.72. This represents a 6.42% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Erin Pennock Foff also recently made the following trade(s):

• On Tuesday, May 5th, Erin Pennock Foff sold 10,576 shares of Maplight Therapeutics stock. The stock was sold at an average price of $28.20, for a total transaction of $298,243.20.
• On Monday, May 4th, Erin Pennock Foff sold 15,652 shares of Maplight Therapeutics stock. The stock was sold at an average price of $27.96, for a total transaction of $437,629.92.

Maplight Therapeutics Stock Performance

NASDAQ MPLT traded up $1.12 during mid-day trading on Wednesday, reaching $29.04. 267,979 shares of the stock were exchanged, compared to its average volume of 342,018. Maplight Therapeutics, Inc. has a one year low of $12.24 and a one year high of $33.28. The company has a 50 day moving average of $22.60. The stock has a market cap of $1.24 billion and a PE ratio of -0.73.

Maplight Therapeutics (NASDAQ:MPLT) last announced its earnings results on Thursday, March 26th. The company reported ($2.47) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.05) by ($1.42). Sell-side analysts expect that Maplight Therapeutics, Inc. will post -3.96 EPS for the current fiscal year.

Institutional Investors Weigh In On Maplight Therapeutics

Large investors have recently made changes to their positions in the business. Fcpm Iii Services B.V. purchased a new stake in shares of Maplight Therapeutics during the 4th quarter valued at $56,672,000. T. Rowe Price Investment Management Inc. purchased a new stake in shares of Maplight Therapeutics during the 4th quarter valued at $49,154,000. Goldman Sachs Group Inc. purchased a new stake in shares of Maplight Therapeutics during the 4th quarter valued at $34,026,000. Nan Fung Group Holdings Ltd purchased a new stake in shares of Maplight Therapeutics during the 4th quarter valued at $17,060,000. Finally, 5AM Venture Management LLC purchased a new stake in Maplight Therapeutics in the 4th quarter worth about $16,687,000.

Analyst Ratings Changes

Several equities research analysts have weighed in on MPLT shares. TD Cowen started coverage on shares of Maplight Therapeutics in a research note on Tuesday, April 7th. They issued a “buy” rating for the company. Weiss Ratings started coverage on shares of Maplight Therapeutics in a research note on Thursday, January 22nd. They issued a “sell (e)” rating for the company. HC Wainwright started coverage on shares of Maplight Therapeutics in a research note on Monday. They issued a “buy” rating and a $45.00 price target for the company. Canaccord Genuity Group began coverage on shares of Maplight Therapeutics in a research note on Thursday, March 19th. They issued a “buy” rating and a $35.00 price target for the company. Finally, Needham & Company LLC initiated coverage on shares of Maplight Therapeutics in a research report on Wednesday, April 8th. They set a “buy” rating and a $37.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Maplight Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $34.43.

Trending Headlines about Maplight Therapeutics

Here are the key news stories impacting Maplight Therapeutics this week:

• Positive Sentiment: Needham reaffirmed its “Buy” rating on MPLT, signaling continued analyst conviction that the shares have upside. Needham Reaffirms Buy
• Positive Sentiment: HC Wainwright initiated/updated coverage with a “Buy” rating and a $45 price target (roughly mid‑50% upside from recent levels), which can attract buyers and support the rally. Many outlets reported the new coverage and target. HC Wainwright Coverage & Target
• Neutral Sentiment: Morningstar and market quote pages show current trading context (price, volume, 50‑day moving average) that traders use to gauge technical support/resistance. Use these pages for up‑to‑date quotes. Morningstar Quote
• Negative Sentiment: HC Wainwright’s detailed forecasts also project larger net losses over 2026–2027 (FY2026 EPS ~ -$4.34; FY2027 EPS ~ -$5.25) and quarterly losses through 2027 — data that underscores continued cash‑burn and execution risk for a clinical‑stage biotech. This raises downside risk if clinical or financing progress stalls. Analyst Estimates
• Negative Sentiment: Recent reported results included a sizable Q1 EPS miss (reported -$2.47 vs. consensus -$1.05), which remains a reminder of earnings volatility and could pressure sentiment if follow‑up data or guidance are weak. Recent Earnings Miss

Maplight Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.